Homepage
Catalog of Screening Compounds
Screening Libraries
Focused and Target Libraries
Active Reference Sets
Diversity Libraries
Screening Compounds
Building blocks
Drug Discovery Services
Custom Chemistry
Medicinal chemistry
In silico Drug Design (CADD)
Discovery Biology
Animal Models
Toxicology and Safety
ADME, DMPK
Chemistry, Manufacturing and Controls
Company
News & Media
Contact us
For suppliers
Trends in discovery compounds
Homepage
>
Company
>
Media
>
Pharma News
>
2026
Pharma News, 2026
AI programme for clinical trials announced in Abu Dhabi, UAE — The National
Oracle, AstraZeneca and M42 launch an AI programme in Abu Dhabi to link patient records and clinical trials, starting with uncontrolled hypertension.
Artiva to discontinue cell therapy after two patient deaths, cut workforce
Artiva halts development of autoimmune cell therapy AlloNK after two patient deaths, plans to cut roughly 94% of staff and assess strategic options.
FDA Approves Talazoparib/Enzalutamide in HRR-Mutated Prostate Cancer 2026
FDA clearance expands talazoparib plus enzalutamide to HRR-mutated prostate cancer after TALAPRO-3 showed a 52% reduction in progression or death risk.
Xbrane Biopharma AB Wins FDA Nod For Lucamzi Biosimilar, US Launch 2027
Xbrane secures FDA approval for Lucamzi, its Lucentis biosimilar, and plans a US launch in 2027 as it targets the ophthalmology market.
Biotech manufacturing facility opens in Brisbane
A $100+ million biotech manufacturing facility, ENTRI, has opened in Brisbane, providing vital cleanrooms and lab infrastructure for clinical manufacturing.
ESMO26: Clinical progress shifts a historically difficult pancreatic cancer
ESMO 2026 data shows Revolution Medicines' daraxonrasib nearly doubled overall survival in pancreatic cancer, alongside benefits in prostate cancer.
A New Hair Loss Pill Moves Closer To FDA Approval After Positive Trial
The oral minoxidil pill VDPHL01 for pattern hair loss showed significant hair growth in a Phase 3 trial, bringing it closer to FDA approval.
FDA approves Enspryng for at-home thyroid eye disease treatment
The FDA has approved Genentech's Enspryng as the first at-home subcutaneous treatment for adults living with thyroid eye disease.
Sumitomo Pharma’s Enzomenib Gets FDA Breakthrough Therapy Designation
The FDA granted Breakthrough Therapy Designation to Sumitomo Pharma's enzomenib for treating R/R acute leukemia with KMT2A rearrangement.
MIRA Pharmaceuticals' MIRA-55 shows pain relief in preclinical study
MIRA Pharmaceuticals reported that its oral compound MIRA-55 demonstrated significant pain relief comparable to celecoxib in a preclinical study.
SBE303 Receives FDA Fast Track Designation in Pretreated Urothelial Cancer
The FDA granted fast track designation to SBE303, an investigational Nectin-4-targeted antibody-drug conjugate for pretreated urothelial cancer.
US lawmakers to introduce bill to speed up clinical trials — CNBC
The proposed bipartisan Faster Clinical Trials Act seeks to streamline clinical trials and create a network of research sites to reduce costs and delays.
1
2
3
4
5
6
7
8